Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2004

View Archived Issues

A study reveals a reduction in the incidence and mortality of stroke in Finland

Protein tyrosine phosphatase 1B inhibitors from Roche

New data on the efficacy of pegylated interferon alfa-2b in viral hepatitis

Novel proteasome inhibitor ER807446 demonstrates antitumor activity especially against large tumors

Inhibition of dopamine transport: a novel treatment for obesity

Antiatherosclerotic action of aminobisphosphonates

NF-kappaB inhibitor DHMEQ as treatment option for advanced urological cancer

Novel p38alpha MAP kinase inhibitors under study at Scios

Selective antagonist action on food intake not only mediated by NPY Y5 receptor

Two novel series of CDK inhibitors presented by Schering-Plough and Pharmacopeia

Agents combining antibacterial and beta-lactamase activity identified at Aventis Pharma

Cellular Genomics patent covers new protein kinase modulators

New GlyT-2 inhibitors in early development at NPS Allelix

NPS Allelix presents new GlyT-1 inhibitors and their use in schizophrenia and cognition disorders

Novartis claims new alpha7 nAChR agonists and their use

Highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Viral Therapeutics

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Transave

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Sirenade

Allergan to withdraw PEP-005 INDs, resubmission planned

Second phase III trial for regadenoson

SARS antibody sent to Sinovac for preclinical testing

GA-GCB enters clinical trial for Gaucher's disease

AlzheimAlert PMA accepted for filing

MedImmune to reacquire rights to FluMist and CAIV-T from Wyeth

EntreMed completes phase I trial with reformulated Panzem

Priority Healthcare becomes preferred specialty pharmacy provider of Apokyn

Celmed BioSciences sells neurology assets and technology platform

Fast track status for DB-289 for African sleeping sickness

New indication and strength approved for Hectorol

Nanogen completes acquisition of SynX

New positive opinion for Herceptin plus Taxotere in E.U.

PARP activation shown to be involved in diabetic neuropathy in mice and rats

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 7, 2025.
House passes H.R. 1, restoring R&D tax cuts
BioWorld MedTech
The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
With surface mimicry, molecular glues shed hairpin need
BioWorld Science
Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
Exercise-mimicking compound offers alternative to GLP-1 therapies
BioWorld
An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...